洁特生物(688026) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥154,567,932.28, representing a year-on-year increase of 16.22%[2] - The net profit attributable to shareholders for Q3 2024 was ¥20,156,585.42, reflecting an increase of 83.25% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥18,656,180.39, up 97.28% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.18, an increase of 125.00% compared to the same period last year[3] - The net profit attributable to shareholders for the year-to-date period was ¥50,156,789.96, showing a significant increase of 259.26% compared to the same period last year[6] - Operating profit for the third quarter of 2024 was ¥60,886,788.80, significantly up from ¥14,437,235.81 in the previous year[21] - Net profit for the first three quarters of 2024 was ¥50,337,922.51, compared to ¥14,142,070.71 in the same period of 2023, marking a substantial increase[21] - Basic earnings per share for the third quarter of 2024 were ¥0.41, up from ¥0.10 in the previous year[22] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,630,948,183.13, a slight increase of 0.30% from the end of the previous year[3] - The company reported a total asset of CNY 1,630,948,183.13 as of the end of Q3 2024, a slight increase from CNY 1,626,052,210.61 in Q3 2023[16] - Current assets totaled CNY 765,045,835.91, showing a decrease from CNY 770,947,880.57 year-over-year[17] - The company’s total liabilities decreased to CNY 461,585,797.39 from CNY 468,464,645.23, a reduction of approximately 1.88%[18] - The equity attributable to shareholders increased to CNY 1,167,194,311.79 from CNY 1,156,965,623.98, reflecting a growth of about 0.11%[19] Cash Flow - The cash flow from operating activities for Q3 2024 was negative at -¥6,092,518.07, a decline of 116.09% compared to the previous year[2] - Cash flow from operating activities for the first three quarters of 2024 was ¥9,374,365.66, a decrease from ¥75,595,181.95 in the same period of 2023[23] - The net cash flow from investment activities was -72,924,550.04 CNY, compared to a positive cash flow of 15,611,976.88 CNY in the previous period[25] - The net cash flow from financing activities was -41,693,609.80 CNY, indicating a significant decrease compared to -16,215,068.88 CNY in the previous period[25] - The cash and cash equivalents at the end of the period amounted to 254,359,515.55 CNY, down from 390,711,670.39 CNY in the previous period[25] - The company reported a decrease in cash and cash equivalents by 110,578,062.03 CNY during the period[25] Research and Development - Research and development expenses for Q3 2024 amounted to ¥6,559,891.11, a decrease of 9.86% year-on-year[3] - The company reported a decrease in the proportion of R&D expenses to operating revenue, which was 4.24% for Q3 2024, down 1.23 percentage points from the previous year[3] - Research and development expenses for the first three quarters of 2024 were ¥19,834,731.06, down from ¥23,751,139.95 in the same period of 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,629[8] - The largest shareholder, Yuan Jianhua, holds 41,072,020 shares, accounting for 29.26% of the total shares[8] - JET(H.K.) BIOSCIENCE CO., LIMITED is the second-largest shareholder with 17,547,293 shares, representing 12.50%[8] - The company has repurchased 2,730,914 shares, which is 1.95% of the total share capital[12] - The top ten shareholders hold a significant portion of the company's shares, with the largest three shareholders alone holding over 46%[8] Legal Matters - The company is involved in a legal dispute with Shandong Darong New Materials Co., Ltd. over a contract worth 10,866,391.80 RMB[14] - The court ruled in favor of the company, ordering Shandong Darong to return 7,962,686.40 RMB plus interest[14] - The company has made provisions for bad debts totaling 7,533,582.08 RMB related to the dispute with Shandong Darong[14] - The company has also made a provision of 3,208,618.86 RMB for inventory depreciation related to PTFE composite mask non-woven fabric[14] - The company has initiated legal proceedings against Shanghai You Electronic Technology Co., with a disputed amount of CNY 18,441,691.80 related to a contract dispute[15] - The company has fully provided for bad debts related to a lawsuit involving CNY 10,340,829 and a counterclaim of CNY 11,473,149.78[15] Other Financial Metrics - Financial expenses increased to ¥16,783,859.10 in the first three quarters of 2024, compared to ¥2,665,971.96 in the same period of 2023[20] - Tax expenses for the first three quarters of 2024 were ¥7,735,336.14, up from ¥5,080,551.96 in the same period of 2023[20] - Other income for the first three quarters of 2024 was ¥8,721,963.78, compared to ¥5,710,563.42 in the same period of 2023, indicating growth in additional revenue streams[20]